1. Home
  2. ZOM vs FATE Comparison

ZOM vs FATE Comparison

Compare ZOM & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZOM
  • FATE
  • Stock Information
  • Founded
  • ZOM 2015
  • FATE 2007
  • Country
  • ZOM United States
  • FATE United States
  • Employees
  • ZOM N/A
  • FATE N/A
  • Industry
  • ZOM Biotechnology: Pharmaceutical Preparations
  • FATE Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ZOM Health Care
  • FATE Health Care
  • Exchange
  • ZOM Nasdaq
  • FATE Nasdaq
  • Market Cap
  • ZOM 128.4M
  • FATE 142.4M
  • IPO Year
  • ZOM N/A
  • FATE 2013
  • Fundamental
  • Price
  • ZOM $0.12
  • FATE $1.42
  • Analyst Decision
  • ZOM
  • FATE Hold
  • Analyst Count
  • ZOM 0
  • FATE 10
  • Target Price
  • ZOM N/A
  • FATE $6.75
  • AVG Volume (30 Days)
  • ZOM 3.4M
  • FATE 2.1M
  • Earning Date
  • ZOM 03-31-2025
  • FATE 03-04-2025
  • Dividend Yield
  • ZOM N/A
  • FATE N/A
  • EPS Growth
  • ZOM N/A
  • FATE N/A
  • EPS
  • ZOM N/A
  • FATE N/A
  • Revenue
  • ZOM $26,727,000.00
  • FATE $13,447,000.00
  • Revenue This Year
  • ZOM $10.28
  • FATE N/A
  • Revenue Next Year
  • ZOM $28.00
  • FATE N/A
  • P/E Ratio
  • ZOM N/A
  • FATE N/A
  • Revenue Growth
  • ZOM 11.33
  • FATE N/A
  • 52 Week Low
  • ZOM $0.12
  • FATE $1.04
  • 52 Week High
  • ZOM $0.20
  • FATE $8.83
  • Technical
  • Relative Strength Index (RSI)
  • ZOM 41.88
  • FATE 48.76
  • Support Level
  • ZOM $0.12
  • FATE $1.43
  • Resistance Level
  • ZOM $0.12
  • FATE $1.81
  • Average True Range (ATR)
  • ZOM 0.00
  • FATE 0.14
  • MACD
  • ZOM 0.00
  • FATE 0.05
  • Stochastic Oscillator
  • ZOM 3.03
  • FATE 39.06

About ZOM Zomedica Corp.

Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its operations are comprised of two reportable segments namely Diagnostic and Therapeutic Devices. It earns the majority of revenue from the therapeutics segment.

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Share on Social Networks: